Jun 25, 2020 | Press Releases
EL SEGUNDO, Calif.–Jun. 25, 2020- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000...
Jun 24, 2020 | Press Releases
EL SEGUNDO, Calif.—Jun. 24, 2020- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an...
Jun 10, 2020 | Press Releases
NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments NantKwest’s PD-L1 t-haNK...
May 27, 2020 | Press Releases
ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for...
May 26, 2020 | Press Releases
EL SEGUNDO, Calif., May 26, 2020 – NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The...
May 19, 2020 | Press Releases
Be The Match BioTherapies will Provide Allogeneic Cellular Source Material to NantKwest for Clinical Trial Addressing Primary Cause of COVID-19 Fatality MINNEAPOLIS, Minn., and EL SEGUNDO, Calif., May 19, 2020 – Be The Match BioTherapies®, an organization offering...
